Key result
Combined cystatin C and creatinine incrementally improves GFR estimation over creatinine alone.
Why the study?
Chronic kidney disease is a growing global health problem, and new biomarkers like serum cystatin C may improve detection of early renal damage and glomerular filtration estimation in asymptomatic patients with risk factors.
Does combined serum cystatin C and creatinine measurement improve the estimation of glomerular filtration compared to creatinine alone in asymptomatic patients with risk factors?
Cross-Sectional (n=195)
Does combined serum cystatin C and creatinine measurement improve the estimation of glomerular filtration compared to creatinine alone in asymptomatic patients with risk factors?
Combined measurement of serum cystatin C and creatinine improves the estimation of glomerular filtration rate in asymptomatic patients with cardiovascular risk factors.
Serum cystatin C may aid early CKD detection in asymptomatic high-risk subjects; leaves open validation before clinical use.
Background: Chronic kidney disease is recognized as a worldwide public health problem, particularly within an increasing prevalence of obesity, diabetes mellitus, and hypertension. This disease affects more than 13% of the world's population and is increasing. Further biochemical assessment with new biomarkers, such as serum cystatin C (CysC), would improve patient care and disease control. The aim of this study was to detect chronic kidney disease (CKD) in asymptomatic subjects with risk factors and evaluate CysC as early biomarker of renal damage and accurate test to estimation glomerular filtration (GF). Methods: This observational analytic and cross-sectional design included 195 patients of both sexes. A full clinical evaluation included height, weight, waist circumference, body mass index (BMI), blood pressure (BP), and family history of disease. Renal function was evaluated through serum creatinine (SCrea), serum CysC, urinary albumin, and urinary creatinine. GF was calculated using CKD-EPI creatinine (CKD-EPI Crea) and CKD-EPI creatinine-cystatin C equations (CKD-EPI Crea-CysC). Results: Renal injury showed 24% of patients with albuminuria; 18% of them were categorized as A2 and 6% as A3. Therefore, 73% had no progression risk (baseline risk), 20% moderate risk, and 7% high risk. Among analyzed groups, significant differences were found in BMI, BP, Screa, CysC, CKD-EPI Crea, and CKD-EPI Crea-CysC. Overweight population was analyzed by assessing CysC and calculating CKD-EPI Crea-CysC, showing an important change with respect to the general population. Conclusion: Combined CysC and Crea measurement provides incremental improvement in predicting measured GF.
No takes yet. Share an insight, caveat, or question.
Ávila et al. (2023) conducted a cross-sectional in Asymptomatic subjects with risk factors for chronic kidney disease (n=195). Serum cystatin C and creatinine measurement was evaluated on Detection of chronic kidney disease and estimation of glomerular filtration. Combined serum cystatin C and creatinine measurement provided incremental improvement in predicting measured glomerular filtration in a cohort where 24% of patients had albuminuria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: